Evidence map›Paper›PMID 32705202›Full record

ArticleMolecular medicine reports2020

Asiaticoside produces an antidepressant‑like effect in a chronic unpredictable mild stress model of depression in mice, involving reversion of inflammation and the PKA/pCREB/BDNF signaling pathway.

Luoqing Wang, Ting Guo, Yuanfang Guo, Yujie Xu

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 60 citations in OpenAlex.

  1. Therapeutic potential ofPharmaceutical biology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Food science and biotechnology · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Neurotrophic Natural Products.Progress in the chemistry of organic natural products · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Luoqing Wang *Department of Cardiovascular Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, P.R. China.
Ting Guo *Department of Neurology, Xuzhou Medical University Affiliated Hospital of Lianyungang, Lianyungang, Jiangsu 222061, P.R. China.
Yuanfang GuoDepartment of Respiratory Medicine, Ganyu District People's Hospital, Lianyungang, Jiangsu 222100, P.R. China.
Yujie XuDepartment of Anesthesiology and Perioperative Medicine, Jiangsu Province Hospital, Nanjing, Jiangsu 210000, P.R. China.
Jiangsu Province Hospital · CNLianyungang Oriental Hospital · CNThe First People’s Hospital of Lianyungang · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asiaticoside is one of the triterpenoid components found in Centella asiatica that has promising neuroprotective properties. The present study aimed to evaluate the antidepressant‑like properties of asiaticoside and to investigate the possible mechanisms underlying its mode of action using a mouse model of chronic unpredictable mild stress (CMS). Behavioral tests, including sucrose preference test, forced swimming test and tail suspension test, were performed to evaluate symptoms of depression. The expression levels of neurotransmitters, 5‑hydroxytryptamine (5‑HT) and norepinephrine (NE), in the hippocampus were measured by high‑performance liquid chromatography. ELISA and western blotting were used to detect protein expression. It was demonstrated that asiaticoside treatment (20 and 40 mg/kg; intragastric) significantly reversed the decrease in sucrose consumption, and reduced the immobility time in tail suspension tests and forced swimming tests in CMS mice. Furthermore, asiaticoside treatment upregulated the expression of 5‑HT and NE in the CMS mouse model. Asiaticoside administration also downregulated the levels of interleukin (IL)‑1β, IL‑6 and tumor necrosis factor‑α in the hippocampus, and reduced the phosphorylation of nuclear factor (NF)‑κBp65 and the expression of nod‑like receptor protein 3 (NLRP3), thus decreasing the expression of mature caspase‑1. Furthermore, asiaticoside significantly increased the levels of cAMP and protein kinase A (PKA), and enhanced phosphorylation of the cAMP‑related specific marker vasodilator‑stimulated phosphoprotein at serine 157. Therefore, asiaticoside may activate the cAMP/PKA signaling pathway to inhibit NF‑κB‑ and NLRP3‑related inflammation. Moreover, phosphorylation of the cAMP‑responsive element‑binding protein at serine 133 and the expression of brain‑derived neurotrophic factor were increased after asiaticoside administration. Collectively, the present results suggested that asiaticoside may play a vital role as an antidepressant and anti‑inflammatory agent in the CMS mouse model by regulating the cAMP/PKA signaling pathway.

Indexed as

AnimalsAntidepressive AgentsBehavior, AnimalBrain-Derived Neurotrophic FactorCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinDisease Models, AnimalGene Expression RegulationMaleMiceNorepinephrinePhosphorylationSerotoninSignal TransductionStress, PsychologicalTriterpenesAntidepressive AgentsasiaticosideBdnf protein, mouseBrain-Derived Neurotrophic FactorCreb1 protein, mouseCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinNorepinephrineSerotoninTriterpenesasiaticosidecaMP/ protein kinase ainflammatory cytokinesnod-like receptor protein 3 inflammasomephosphorylated nF-κBp65

Identifiers

PMID32705202
PMCPMC7411460
OpenAlexW3040287805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.